Olaparib in BRCA-mutated, HER-2 negative metastatic breast cancer
Olaparib significantly prolonged progression-free survival compared to chemotherapy, particularly in first line patients.
Olaparib significantly prolonged progression-free survival compared to chemotherapy, particularly in first line patients.